| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advances and challenges in the management of essential thrombocythemia
|
Birgegård, Gunnar
|
|
2015
|
|
3 |
p. 142-156
|
artikel
|
| 2 |
Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma
|
Lobetti-Bodoni, Chiara
|
|
2013
|
|
3 |
p. 189-198
|
artikel
|
| 3 |
Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development
|
Phipps, Colin
|
|
2015
|
|
3 |
p. 120-127
|
artikel
|
| 4 |
Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study
|
Kolibaba, Kathryn S.
|
|
2013
|
|
3 |
p. 157-171
|
artikel
|
| 5 |
Differentiating malignant hypertension-induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura
|
Khanal, Nabin
|
|
2015
|
|
3 |
p. 97-102
|
artikel
|
| 6 |
Editorial
|
Mauro, Michael J.
|
|
2011
|
|
3 |
p. 127-127
|
artikel
|
| 7 |
Editorial
|
Mauro, Michael J.
|
|
2012
|
|
3 |
p. 129-130
|
artikel
|
| 8 |
Editorial
|
Mauro, Michael J.
|
|
2013
|
|
3 |
p. 155-156
|
artikel
|
| 9 |
Efficacy and safety of novel anticoagulants compared with established agents
|
Rybak, Iwona
|
|
2011
|
|
3 |
p. 175-195
|
artikel
|
| 10 |
Efficacy and safety of reduced-intensity induction therapy with a bortezomib-based regimen in elderly patients with multiple myeloma
|
Sopeña, María
|
|
2012
|
|
3 |
p. 147-154
|
artikel
|
| 11 |
Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile
|
Cheng, Gregory
|
|
2012
|
|
3 |
p. 155-164
|
artikel
|
| 12 |
Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia
|
Gallipoli, Paolo
|
|
2015
|
|
3 |
p. 103-119
|
artikel
|
| 13 |
Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond
|
Foss, Francine
|
|
2011
|
|
3 |
p. 161-173
|
artikel
|
| 14 |
High prevalence of obesity in acute promyelocytic leukemia (APL): implications for differentiating agents in APL and metabolic syndrome
|
Tedesco, Jason
|
|
2011
|
|
3 |
p. 141-145
|
artikel
|
| 15 |
Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence
|
Chaidos, Aristeidis
|
|
2015
|
|
3 |
p. 128-141
|
artikel
|
| 16 |
Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective
|
Desai, Madhav
|
|
2014
|
|
3 |
p. 91-101
|
artikel
|
| 17 |
Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician’s guide
|
Griffin, Morag
|
|
2017
|
|
3 |
p. 119-126
|
artikel
|
| 18 |
Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential
|
Duvic, Madeleine
|
|
2016
|
|
3 |
p. 171-174
|
artikel
|
| 19 |
Myelofibrosis 2012: it’s complicated
|
Hubbeling, Harper G.
|
|
2012
|
|
3 |
p. 131-146
|
artikel
|
| 20 |
New treatments in hemophilia: insights for the clinician
|
Knobe, Karin
|
|
2012
|
|
3 |
p. 165-175
|
artikel
|
| 21 |
Novel therapies for peripheral T-cell lymphomas
|
Shustov, Andrei
|
|
2013
|
|
3 |
p. 173-187
|
artikel
|
| 22 |
Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist
|
McCurdy, Arleigh R.
|
|
2013
|
|
3 |
p. 211-216
|
artikel
|
| 23 |
Reduced-intensity conditioning allogeneic hematopoietic-cell transplantation for older patients with acute myeloid leukemia
|
Goyal, Gaurav
|
|
2016
|
|
3 |
p. 131-141
|
artikel
|
| 24 |
Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma
|
Sánchez Ruiz, Antonio C.
|
|
2014
|
|
3 |
p. 78-90
|
artikel
|
| 25 |
Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study
|
Kuo, Ching-Yuan
|
|
2018
|
|
3 |
p. 65-78
|
artikel
|
| 26 |
Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease
|
How, Joan
|
|
2017
|
|
3 |
p. 107-118
|
artikel
|
| 27 |
Symptom burden and quality of life in patients with follicular lymphoma undergoing maintenance treatment with rituximab compared with observation
|
Walker, Mark S.
|
|
2011
|
|
3 |
p. 129-139
|
artikel
|
| 28 |
Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib
|
Sharman, Jeff
|
|
2016
|
|
3 |
p. 157-170
|
artikel
|
| 29 |
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
|
Wander, Seth A.
|
|
2014
|
|
3 |
p. 65-77
|
artikel
|
| 30 |
The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy
|
Tosello, Valeria
|
|
2013
|
|
3 |
p. 199-210
|
artikel
|
| 31 |
The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia
|
Benjamin, Jonathan E.
|
|
2016
|
|
3 |
p. 142-156
|
artikel
|
| 32 |
The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies
|
Skarbnik, Alan P.
|
|
2017
|
|
3 |
p. 99-105
|
artikel
|
| 33 |
The role of intravenous iron in the treatment of anemia in cancer patients
|
Steinmetz, H.Tilman
|
|
2012
|
|
3 |
p. 177-191
|
artikel
|
| 34 |
Treatment options for high-risk chronic lymphocytic leukaemia
|
Hewamana, Saman
|
|
2011
|
|
3 |
p. 147-159
|
artikel
|
| 35 |
Voriconazole and its clinical potential in the prophylaxis of systemic fungal infection in patients with hematologic malignancies: a perspective review
|
Zabalza, Amaya
|
|
2013
|
|
3 |
p. 217-230
|
artikel
|
Tijdschrift beschrijving